Steps in the evaluation processNotification of receipt of application - These notices provide advice that a DIR licence application has been received by the OGTR and that a RARMP is in preparation.
Public calls for comment - The Regulator has invited the public to provide comment on a RARMP regarding the identified risk(s) to human health and the environment and the proposed management measures.
Call for comment closed - Comments on these RARMPs have closed, the Regulator is considering submissions and a decision on the licence is imminent.
Summary of the evaluation process for DIR licence applications flow chart
For more information about DIR applications, please contact the OGTR. DIR applications are available on request (excluding any information that the Regulator has declared to be, or is under consideration as, Confidential Commercial Information) to anyone that requests a copy (section 54 of the Act). A summary of application and, once prepared, the RARMP for each application is available on this website.
|DIR Licence Application Number||Title of Project||Notification of receipt of application||Public calls for comment on RARMP open||Call for comment closed (under consideration by the Regulator)||Is application being assessed as ‘limited and controlled’?|
|DIR 138||Commercial release of canola genetically modified for dual herbicide tolerance and a hybrid breeding system||18 Jun 2015||No|
|DIR 137||Commercial supply of attenuated GM influenza vaccines (AstraZeneca Pty Ltd)||06 May 2015||No|
|DIR 136||Limited and controlled release of cotton genetically modified for enhanced fibre quality (CSIRO)||26 Mar 2015||24 Jun 2015||Yes|
|DIR 135||Limited and controlled release of sugarcane genetically modified for enhanced sugar content – The University of Queensland||06 Feb 2015||27 Apr 2015||15 Jun 2015||Yes|
|DIR 134||Commercial import and distribution of genetically modified carnations with altered flower colour - International Flower Developments Pty Ltd||22 Jan 2015||No|
|DIR 132||Commercial supply of a tumour-selective genetically modified virus for cancer therapy (Amgen Australia Pty Ltd)||27 Oct 2014||22 Apr 2015||19 Jun 2015||No|
View the list of DIRs.